RFTH/LinkedIn

Sep 8, 2026, 15:21

ISTH 2026 Highlights, Expert Insights Into Thrombosis and Hemostasis – RFHT

RFHT (Revue Francophone d’Hémostase et Thrombose), shared a post on LinkedIn:

“The essentials of ISTH 2026 deciphered in interviews

How can you go even further with emicizumab? Cedric HERMANS, Liège, Belgium
NETs in all their facets: formation, fate and elimination, chloé James, Bordeaux
API CAT: what do we know about venous thromboembolic recurrences with apixaban? Isabelle Mahé, Colombes
What clinical lessons can be learned from the 3year data from the CASSIOPEIA study on venous thromboembolism? Laurent Frenzel, New York, United States
Von Willebrand disease: should the 2B variants be reclassified New York? Melanie Daniel, Lille
Endothelial cells: a new role in the mechanisms of thrombosis? David Smadja, Paris
Post MTEV patient caregiver communication session: a new tool to improve living better with one’s pathology? Francis Couturaud, Brest
Can we still improve the prevention of thrombotic risk? Catherine Lemarie, Brest”

Proceed to the video attached to the post.

ISTH 2026 Highlights, Expert Insights Into Thrombosis and Hemostasis - RFHT